Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Clinical response to Hu-rhEGF-rP64k vaccine

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

First evaluation [n (%)] Day 46
Response Group A–0.6 mg Group B- 1.2 mg Group C-1.8 mg Group D-2.4 mg Total
n = 3 n = 6 n = 5 n = 6 n = 20
CR 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
PR 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
SD 3(100%) 4(67%) 3(60%) 5(83%) 15(75%)
PD 0(0%) 2(33%) 2(40%) 1(17%) 5(25%)
Second evaluation [n (%)] Day 106
Response Group A–0.6 mg Group B- 1.2 mg Group C-1.8 mg Group D-2.4 mg Total
n = 3 n = 5 n = 3 n = 4 n = 15
CR 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
PR 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)
SD 3(100%) 3(60%) 2(67%) 4(100%) 12(80%)
PD 0(0%) 2(40%) 1(33%) 0(0%) 3(20%)